MTOR and uterine corpus leiomyoma: The last generation of protein kinase inhibitors of the pAKT/PIC3/mTOR signal pathway, capivasertib and ipatasertib, have not been clinically tested for therapy of uterine leiomyoma apparently due to obviously high side toxicity.